175 related articles for article (PubMed ID: 31804402)
1. The Prognostic Role of β-Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only: A Meta-analysis of Individual Patient Data.
Timbergen MJM; Colombo C; Renckens M; Kim HS; Rosmalen JV; Salas S; Mullen JT; Colombo P; Nishida Y; Wiemer EAC; Verhoef C; Sleijfer S; Gronchi A; Grünhagen DJ
Ann Surg; 2021 Jun; 273(6):1094-1101. PubMed ID: 31804402
[TBL] [Abstract][Full Text] [Related]
2. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
3. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
[TBL] [Abstract][Full Text] [Related]
4. Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors.
Timbergen MJM; Boers R; Vriends ALM; Boers J; van IJcken WFJ; Lavrijsen M; Grünhagen DJ; Verhoef C; Sleijfer S; Smits R; Gribnau J; Wiemer EAC
Front Oncol; 2020; 10():565031. PubMed ID: 33194643
[TBL] [Abstract][Full Text] [Related]
5. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent, multicenter validation study.
Colombo C; Miceli R; Lazar AJ; Perrone F; Pollock RE; Le Cesne A; Hartgrink HH; Cleton-Jansen AM; Domont J; Bovée JV; Bonvalot S; Lev D; Gronchi A
Cancer; 2013 Oct; 119(20):3696-702. PubMed ID: 23913621
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of
Guo L; Wang X; Xu B; Lang R; Hu B
Future Oncol; 2021 Feb; 17(4):435-442. PubMed ID: 33397129
[No Abstract] [Full Text] [Related]
7. Novel pathogenic alterations in pediatric and adult desmoid-type fibromatosis - A systematic analysis of 204 cases.
Trautmann M; Rehkämper J; Gevensleben H; Becker J; Wardelmann E; Hartmann W; Grünewald I; Huss S
Sci Rep; 2020 Feb; 10(1):3368. PubMed ID: 32099073
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
van Broekhoven DL; Verhoef C; Grünhagen DJ; van Gorp JM; den Bakker MA; Hinrichs JW; de Voijs CM; van Dalen T
Ann Surg Oncol; 2015 May; 22(5):1464-70. PubMed ID: 25341748
[TBL] [Abstract][Full Text] [Related]
9. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
[TBL] [Abstract][Full Text] [Related]
10. Lack of Prognostic Value of CTNNB1 Mutation Profile in Desmoid-Type Fibromatosis.
Penel N; Bonvalot S; Bimbai AM; Meurgey A; Le Loarer F; Salas S; Piperno-Neumann S; Chevreau C; Boudou-Rouquette P; Dubray-Longeras P; Kurtz JE; Guillemet C; Bompas E; Italiano A; Le Cesne A; Orbach D; Thery J; Le Deley MC; Blay JY; Mir O
Clin Cancer Res; 2022 Sep; 28(18):4105-4111. PubMed ID: 35294527
[TBL] [Abstract][Full Text] [Related]
11. Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.
Pinto FFE; Mello CAL; Nakagawa SA; Chung WT; Torrezan GT; Barros BDF; Cunha IW; Calsavara VF; Carraro DM; Lopes A
Clin Orthop Relat Res; 2023 Oct; 481(10):1978-1989. PubMed ID: 37104792
[TBL] [Abstract][Full Text] [Related]
12. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis and mutation stratification of desmoid-type fibromatosis on MRI using radiomics.
Timbergen MJM; Starmans MPA; Padmos GA; Grünhagen DJ; van Leenders GJLH; Hanff DF; Verhoef C; Niessen WJ; Sleijfer S; Klein S; Visser JJ
Eur J Radiol; 2020 Oct; 131():109266. PubMed ID: 32971431
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of local recurrence after surgery in extraabdominal desmoid-type fibromatosis: A multicenter study in Japan.
Nishida Y; Hamada S; Kawai A; Kunisada T; Ogose A; Matsumoto Y; Ae K; Toguchida J; Ozaki T; Hirakawa A; Motoi T; Sakai T; Kobayashi E; Gokita T; Okamoto T; Matsunobu T; Shimizu K; Koike H
Cancer Sci; 2020 Aug; 111(8):2935-2942. PubMed ID: 32539220
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
17. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
18. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
[TBL] [Abstract][Full Text] [Related]
19. A Nationwide Prospective Clinical Trial on Active Surveillance in Patients With Non-intraabdominal Desmoid-type Fibromatosis: The GRAFITI Trial.
Schut AW; Timbergen MJM; van Broekhoven DLM; van Dalen T; van Houdt WJ; Bonenkamp JJ; Sleijfer S; Grunhagen DJ; Verhoef C
Ann Surg; 2023 Apr; 277(4):689-696. PubMed ID: 35166264
[TBL] [Abstract][Full Text] [Related]
20. Droplet Digital PCR (ddPCR) as a Novel Technology in Detecting CTNNB1 Mutations in Desmoid Fibromatosis.
Gandhi J; Kao E; Wu Y; Mantilla JG; Ricciotti RW; Bandhlish A; Liu YJ; Chen EY
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):662-667. PubMed ID: 36227098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]